Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05CFH
|
|||
| Former ID |
DCL000684
|
|||
| Drug Name |
AGN-199981
|
|||
| Indication | Neuropathic pain [ICD-11: 8E43.0] | Phase 2 | [1] | |
| Therapeutic Class |
Analgesics
|
|||
| Company |
Allergan
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Adrenergic receptor alpha-2B (ADRA2B) | Target Info | Agonist | [1] |
| KEGG Pathway | cGMP-PKG signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Panther Pathway | Alpha adrenergic receptor signaling pathway | |||
| Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Reactome | Adrenoceptors | |||
| Adrenaline signalling through Alpha-2 adrenergic receptor | ||||
| G alpha (i) signalling events | ||||
| G alpha (z) signalling events | ||||
| WikiPathways | Monoamine GPCRs | |||
| GPCRs, Class A Rhodopsin-like | ||||
| Platelet Aggregation (Plug Formation) | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.